Chicago Marriott Downtown Magnificent Mile
June 1, 2008 .
Not an official event of the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. Not sponsored or endorsed by ASCO or The ASCO Foundation.
Acknowledgement of Commercial Support
The CBCE and Sarcoma Foundation of America gratefully acknowledge the educational grant provided by: ARIAD Pharmaceuticals, Inc.; Novartis Oncology; Pfizer; PharmaMar, S.A.; Roche Pharmaceuticals; Infinity Pharmaceuticals, Inc.; Daiichi Sankyo Pharma Development; EMD Serono, Inc.; and IDM Pharma
SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .
01 junio 2008
ASCO 2008 , Pharma Mar y J&J en el Scientific Program Committee Disclosure Index .
Pagina 3 J&J Y Pharma Mar en Developmental Therapeutics–Cytotoxic Chemotherapy .
Pagina 7 Pharma Mar en Genitourinary Cancer .
Pagina 8 J&J en Gynecologic Cancer .
Pagina 12 J&J en Sarcoma .
Pagina 7 Pharma Mar en Genitourinary Cancer .
Pagina 8 J&J en Gynecologic Cancer .
Pagina 12 J&J en Sarcoma .
Suscribirse a:
Comentarios (Atom)